MX389276B - Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico. - Google Patents

Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.

Info

Publication number
MX389276B
MX389276B MX2019007684A MX2019007684A MX389276B MX 389276 B MX389276 B MX 389276B MX 2019007684 A MX2019007684 A MX 2019007684A MX 2019007684 A MX2019007684 A MX 2019007684A MX 389276 B MX389276 B MX 389276B
Authority
MX
Mexico
Prior art keywords
sub
sup
group
acceptable salt
atom
Prior art date
Application number
MX2019007684A
Other languages
English (en)
Other versions
MX2019007684A (es
Inventor
Keiji Tamura
Natsuki Ishida
Satoshi ISSHIKI
Shohei Ouchi
Takashi MATSUHIRA
Takeru Yamakawa
Yoshinari Wakiyama
Yuji Tabata
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of MX2019007684A publication Critical patent/MX2019007684A/es
Publication of MX389276B publication Critical patent/MX389276B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto representado por la Fórmula general (1) a continuación o una sal de este aceptable desde el punto de vista farmacológico: (Ver Fórmula) en la Fórmula (1), R1 y R2 pueden ser iguales o diferentes, y cada uno representa un átomo de hidrógeno, un átomo de alógeno, un grupo hidroxilo, un grupo carboxi, un grupo ciano, un grupo C1-6 alquilo opcionalmente sustituido et al.; R3 representa un átomo de hidrogeno; R4 representa un grupo heterocíclico monocíclico opcionalmente sustituido de 4 a 10 miembros que contiene 1 a 4 heteroátomos seleccionados de un átomo de oxígeno, un átomo de nitrógeno y un átomo de azufre; X representa a un grupo representado por la fórmula siguiente: -CH2-, -CH2-CH2-, -CH2-CH2-CH2- o -CH2-O-CH2-; y Z representa un átomo de hidrogeno o un grupo hidroxilo.
MX2019007684A 2016-12-26 2017-12-26 Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico. MX389276B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016251577 2016-12-26
JP2017089251 2017-04-28
PCT/JP2017/046610 WO2018124060A1 (ja) 2016-12-26 2017-12-26 新規化合物及びその薬理的に許容される塩

Publications (2)

Publication Number Publication Date
MX2019007684A MX2019007684A (es) 2019-09-09
MX389276B true MX389276B (es) 2025-03-20

Family

ID=62709343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007684A MX389276B (es) 2016-12-26 2017-12-26 Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.

Country Status (20)

Country Link
US (1) US10669283B2 (es)
EP (1) EP3560925B1 (es)
JP (1) JP6815417B2 (es)
KR (1) KR102414365B1 (es)
CN (1) CN110114358B (es)
AU (1) AU2017385199B2 (es)
CY (1) CY1124643T1 (es)
DK (1) DK3560925T3 (es)
ES (1) ES2875548T3 (es)
HU (1) HUE055468T2 (es)
IL (1) IL267594B (es)
MX (1) MX389276B (es)
PH (1) PH12019501391A1 (es)
PL (1) PL3560925T3 (es)
PT (1) PT3560925T (es)
RU (1) RU2767878C2 (es)
TW (1) TWI752141B (es)
UA (1) UA124353C2 (es)
WO (1) WO2018124060A1 (es)
ZA (1) ZA201904241B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021155336A (ja) * 2018-06-27 2021-10-07 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤
AR114977A1 (es) * 2018-06-27 2020-11-11 Meiji Seika Pharma Co Ltd Cristales de derivado de benzoxazol
WO2020004521A1 (ja) * 2018-06-27 2020-01-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 炎症性疾患、自己免疫疾患、線維化疾患、及びがん疾患の治療剤
JP2022533007A (ja) 2019-04-30 2022-07-21 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性な新規のインドリジン－２－カルボキサミド
CN111057075B (zh) * 2019-12-24 2021-04-27 武汉九州钰民医药科技有限公司 Ret抑制剂及其制备方法
BR112023025934A2 (pt) * 2021-06-30 2024-02-27 Meiji Seika Pharma Co Ltd Método para produzir derivado de benzoxazol tendo anel piperazina bicíclico ou sal do mesmo, e método para produzir material do mesmo
CN116283813B (zh) * 2023-01-18 2025-07-08 南方医科大学 苯并恶唑类化合物或其药学上可接受的盐、水合物、n-氧化合物或溶剂合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61166827A (ja) 1985-01-17 1986-07-28 Toray Ind Inc 変性エポキシ系微粒子
JP3193560B2 (ja) 1993-04-16 2001-07-30 明治製菓株式会社 新規ベンゾオキサゾール誘導体
JP3520177B2 (ja) 1996-05-09 2004-04-19 明治製菓株式会社 セロトニン５−ｈｔ３受容体部分活性薬
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
PL210065B1 (pl) * 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
US7307094B2 (en) * 2005-02-17 2007-12-11 Amr Technology, Inc. Benzoxazole carboxamides for treating CINV and IBS-D
BRPI0716069A2 (pt) * 2006-08-07 2013-09-17 Albany Molecular Res Inc composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
ATE537175T1 (de) * 2007-10-19 2011-12-15 Boehringer Ingelheim Int Neue piperazino-dihydrothienopyrimidin-derivate
ES2714705T3 (es) * 2013-07-10 2019-05-29 Meiji Seika Pharma Co Ltd Inhibidor de PDE4 novedoso

Also Published As

Publication number Publication date
JP6815417B2 (ja) 2021-01-20
TWI752141B (zh) 2022-01-11
NZ754689A (en) 2024-04-26
EP3560925A4 (en) 2020-06-10
WO2018124060A1 (ja) 2018-07-05
MX2019007684A (es) 2019-09-09
EP3560925A1 (en) 2019-10-30
KR102414365B1 (ko) 2022-07-01
HUE055468T2 (hu) 2021-11-29
AU2017385199A1 (en) 2019-07-04
KR20190097235A (ko) 2019-08-20
PH12019501391A1 (en) 2020-02-10
RU2019122999A3 (es) 2021-03-31
PT3560925T (pt) 2021-07-28
RU2767878C2 (ru) 2022-03-22
US10669283B2 (en) 2020-06-02
DK3560925T3 (da) 2021-06-28
JPWO2018124060A1 (ja) 2019-10-31
UA124353C2 (uk) 2021-09-01
CN110114358B (zh) 2021-12-03
ZA201904241B (en) 2020-12-23
ES2875548T3 (es) 2021-11-10
CN110114358A (zh) 2019-08-09
PL3560925T3 (pl) 2021-12-20
CA3048170A1 (en) 2018-07-05
US20190322686A1 (en) 2019-10-24
RU2019122999A (ru) 2021-01-26
AU2017385199B2 (en) 2021-09-09
EP3560925B1 (en) 2021-06-02
IL267594B (en) 2022-04-01
BR112019010571A2 (pt) 2019-09-17
CY1124643T1 (el) 2022-11-25
TW201835080A (zh) 2018-10-01

Similar Documents

Publication Publication Date Title
MX389276B (es) Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.
IL278766B1 (en) Molecule, n-(3-chloro-1 (pyridin-3-yl)-h 1-pyrazol-4-yl)-2-(methylsulfonyl)propanamide for use in pest control
UA116794C2 (uk) Моноциклічна піридинова похідна
MX384087B (es) Piperidinas como inhibidores de menina.
WO2014144545A3 (en) Substituted benzoxazoles and methods of use thereof
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
TN2015000175A1 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
EA201000396A1 (ru) Новые фунгициды
EA201000269A1 (ru) Новые гербициды
PH12016502303A1 (en) Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
AU2010243044A8 (en) Carbinol compound having heterocyclic linker
AR111806A1 (es) Derivados de indol n-sustituidos
PH12020500292A1 (en) Pyridine compound substituted with azole
MY178881A (en) Novel aqueous composition
MX2017005423A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
MX2016017405A (es) Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen.
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
MX2017007574A (es) Composicion.
MX2017007572A (es) Composicion acuosa.
TN2018000126A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
MX2015007309A (es) Derivado de hidantoina.
BR112013024957A2 (pt) derviado de furanona ou um sal farmaceuticamente aceitável do mesmo